Friday, February 15, 2019 6:11:56 AM
On the original reporting of the Liau study about a greater treatment advantage conferred to Mes patients, I viewed things similarly, even in terms of potential 'cure' for Mes patients. But research findings have moved on and diversified somewhat, I believe. And personally, I would never use 'cure' and GBM in the same sentence any more.
It has now been found that intra-tumoral heterogeneity sometimes exists, with different expression profiles existing within the same tumor.
Along with that, some research has indicated that certain treatments including RT and Bevacizumab can encourage a transition from one genetic profile to another, with the shift always being towards Mes.
I don't think methylation status is tied to proneural profile.
I think it is represented across all the profiles at least to some extent.
I don't know what graphic display you are referring to. I certainly haven't seen it in JTM.
There is though, an association between secondary gliomas, younger patients, IDH mutation, proneural profile and better outcome!
But 90% of GBM's are primary tumors.
Then you also have proliferative, as a fourth subgroup, mentioned by some and not by others.
At least one group have identified what they call molecular clusters, which they believe are more accurately predictive, than the previously proposed proneural, classical, and mesenchymal.
So all in all, I now view it as a much more complex and confusing field. And that I think is the nature of GBM. There are no simple, persisting intrinsic subgroups, excepting perhaps the IDH mutation/proneural link. But even with that there is the tendency towards a mes transition with certain treatments.
I believe that DCVax does have an 'across the board' benefit however, with the extent of benefit clearly greater with meth. Though we know that there are at least some unmeth patients in the 'TOP100'.
I think that is how NWBO sees it it, with the stress they have given to only a small minority in the TOP100, having all the favorable factors.
It is not only in GBM that biomarkers are imperfect.
The PDL-1 expression biomarker for ICI response for example is far from perfect.
http://cancerres.aacrjournals.org/content/69/23/9065.long
https://www.futuremedicine.com/doi/full/10.2217/fon.14.86
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
FEATURED Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • ELMGF • Sep 10, 2024 11:00 AM